Condition
HR Positive
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07428018Phase 2Not Yet Recruiting
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
NCT05868226Phase 1Recruiting
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT04602117Phase 1Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Showing all 3 trials